Chardan Capital Weighs in on EYPT FY2026 Earnings

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Analysts at Chardan Capital issued their FY2026 EPS estimates for EyePoint Pharmaceuticals in a research note issued on Monday, March 24th. Chardan Capital analyst D. Gataulin anticipates that the company will post earnings per share of ($2.82) for the year. Chardan Capital has a “Buy” rating and a $33.00 price objective on the stock. The consensus estimate for EyePoint Pharmaceuticals’ current full-year earnings is ($2.13) per share.

Several other equities analysts have also commented on the stock. HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. Citigroup assumed coverage on shares of EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating and a $33.00 target price for the company. Finally, StockNews.com upgraded shares of EyePoint Pharmaceuticals to a “sell” rating in a research note on Friday, March 14th. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $26.63.

EyePoint Pharmaceuticals Price Performance

Shares of NASDAQ EYPT opened at $6.06 on Wednesday. The firm has a market capitalization of $416.50 million, a PE ratio of -3.03 and a beta of 1.41. EyePoint Pharmaceuticals has a 1-year low of $5.54 and a 1-year high of $23.65. The business’s fifty day moving average price is $6.85 and its two-hundred day moving average price is $8.26.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings results on Wednesday, March 5th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The company had revenue of $11.60 million during the quarter, compared to the consensus estimate of $11.02 million.

Institutional Trading of EyePoint Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Suvretta Capital Management LLC raised its holdings in EyePoint Pharmaceuticals by 31.1% during the fourth quarter. Suvretta Capital Management LLC now owns 6,783,091 shares of the company’s stock worth $50,534,000 after purchasing an additional 1,607,268 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in EyePoint Pharmaceuticals by 51.7% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,750,000 shares of the company’s stock valued at $42,838,000 after purchasing an additional 1,958,580 shares in the last quarter. Franklin Resources Inc. increased its position in shares of EyePoint Pharmaceuticals by 3.1% during the 4th quarter. Franklin Resources Inc. now owns 4,137,567 shares of the company’s stock valued at $30,825,000 after purchasing an additional 125,519 shares during the period. Vanguard Group Inc. raised its stake in shares of EyePoint Pharmaceuticals by 24.8% in the 4th quarter. Vanguard Group Inc. now owns 3,803,227 shares of the company’s stock worth $28,334,000 after buying an additional 755,045 shares in the last quarter. Finally, Federated Hermes Inc. lifted its holdings in shares of EyePoint Pharmaceuticals by 92.7% in the fourth quarter. Federated Hermes Inc. now owns 3,707,445 shares of the company’s stock valued at $27,620,000 after buying an additional 1,783,765 shares during the period. 99.41% of the stock is owned by institutional investors and hedge funds.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.